Aligos Therapeutics, Inc.
ALGS
Rank in Stocks
#25646
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-Γ agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Share Price
$3.95
Last synced: 2026-11-09
Market Cap
$24.67M
Change (1 day)
-2.95%
Change (1 year)
-40.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Aligos Therapeutics, Inc. (ALGS)
Category
Healthcare
Operating Margin for Aligos Therapeutics, Inc. (ALGS)
Operating Margin as of November 2026 TTM: -250.63%
According to Aligos Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -250.63%. At the end of 2025 the company had an operating margin of -4,024.93%.
Operating Margin history for Aligos Therapeutics, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -250.63% | -93.77% |
| 2025 | -4,024.93% | 78.10% |
| 2024 | -2,259.92% | 298.22% |
| 2023 | -567.50% | -19.12% |
| 2022 | -701.66% | -76.16% |
| 2021 | -2,943.82% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.15% |
US
|
|
| -149.01% | -99.41% |
US
|
|
| 25.57% | -100.10% |
AU
|
|
| 31.23% | -100.12% |
BE
|
|
| 29.35% | -100.12% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Aligos Therapeutics, Inc.'s operating margin
What is Aligos Therapeutics, Inc.'s operating margin?
Aligos Therapeutics, Inc.'s operating margin is -250.63%, as of Nov 2026.
What was Aligos Therapeutics, Inc.'s operating margin in 2025?
In 2025, Aligos Therapeutics, Inc.'s operating margin was -4,024.93%, compared with -2,259.92% in 2024.
How has Aligos Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Aligos Therapeutics, Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2025 (-4,024.93%).
How does Aligos Therapeutics, Inc.'s operating margin compare with similar companies?
Aligos Therapeutics, Inc.'s operating margin (-250.63%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.